On September 21, 2026 Mercy BioAnalytics, Inc. ("Mercy" or the "Company"), a pioneer in blood-based early cancer detection, reported that the U.S. Food and Drug Administration ("FDA") has approved the Company’s Investigational Device Exemption (IDE) application for the Evident Ovarian Cancer Screening Test. The approval allows Mercy to use the test in its pivotal SOARA Clinical Validation Study, a prospective clinical study designed to evaluate the safety of the test when used for ovarian cancer screening in average-risk women, following Institutional Review Board (IRB) approval.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is expected to support the Company’s ongoing clinical and regulatory program for the Evident Ovarian Cancer Screening Test.

"FDA approval of our IDE application is an important milestone in advancing the Evident Test through the regulatory review process." said Dawn Mattoon, Ph.D., Chief Executive Officer of Mercy BioAnalytics. "We designed the SOARA study to build prospective evidence for our test as we continue working toward making earlier ovarian cancer detection available to more women."

Ovarian cancer remains among the most lethal gynecologic cancers and is frequently diagnosed at an advanced stage. There is currently no FDA-approved screening test for ovarian cancer. FDA previously granted Breakthrough Device Designation to Mercy’s ovarian cancer test.

The Evident Ovarian Cancer Screening Test is powered by Mercy’s patented Mercy Halo liquid biopsy platform, which uses biomarker colocalization to interrogate highly abundant, blood-based extracellular vesicles and particles that carry cancer-associated signatures from their cells of origin.

Approval of the IDE application permits Mercy to conduct the specified clinical investigation. It does not constitute FDA approval or clearance of the Evident Ovarian Cancer Screening Test.

(Press release, Mercy BioAnalytics, SEP 21, 2026, View Source [SID1234670980])